New Blood Test Predicts Illness Path and Treatment Response

Modern medical diagnostics are currently making significant strides toward personalized care. A groundbreaking study reveals how a disease trajectory blood test can predict patient outcomes from just one sample. Researchers at Imperial College London recently developed the VeloCD method for this purpose. This tool analyzes RNA markers to determine if a patient will recover or deteriorate soon. Consequently, doctors can see if an infection is ramping up or winding down without repeated tests.

How the Disease Trajectory Blood Test Works

This innovative approach helps in identifying the specific cause of a fever. For instance, it distinguishes between bacterial and viral origins very efficiently. Furthermore, it accurately assessed children with acute fevers across nine European countries. Specifically, it predicted transitions in healthy adults exposed to flu or COVID-19 pathogens. By predicting the course of illness early, clinicians can provide more targeted treatments. Therefore, the right patient receives the right care at the most optimal time.

Clinical Benefits of the VeloCD Method

Moreover, the test requires only a single time-point sample to yield results. This efficiency reduces the need for repeated measurements over several days significantly. As a result, healthcare staff can triage patients much faster than traditional methods allow. Additionally, the test predicted treatment responses in inflammatory bowel disease after just one dose. Furthermore, the study appeared in the journal Nature Communications recently. However, the team notes that further validation is still necessary before widespread clinical use.

Frequently Asked Questions

Q1: What is the VeloCD method?

The VeloCD method is a computational approach that analyzes whole-blood RNA to anticipate future clinical states from a single time-point sample.

Q2: Can the test help with COVID-19 and flu?

Yes, the study showed that blood samples collected as early as Day 2 after exposure could accurately predict infection before PCR confirmation.

Q3: Who led the development of this technology?

Researchers from the UK\'s Imperial College London led the study and developed the VeloCD method as a proof-of-concept diagnostic tool.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Study describes blood test that might reveal one\'s illness trajectory, responseto treatment - ETHealthworld


2. Dunican, C., Wilson, C., Habgood-Coote, D., et al. (2026). Predicting trajectories of illness using RNA velocity of whole blood. Nature Communications. DOI: 10.1038/s41467-026-71685-5


3. Imperial College London. (2026). Blood test could help predict disease progression and how well treatment will work.